BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10761543)

  • 21. [The clinical immunology laboratory in diagnosis and monitoring of systemic lupus erythematosus and connective tissue diseases].
    Sinico RA; Radice A
    G Ital Nefrol; 2005; 22 Suppl 33():S21-6. PubMed ID: 16419001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antinuclear antibodies in patients with polymorphic light eruption: a long-term follow-up study.
    Tzaneva S; Volc-Platzer B; Kittler H; Hönigsmann H; Tanew A
    Br J Dermatol; 2008 May; 158(5):1050-4. PubMed ID: 18341657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is high titre ANA specific for connective tissue disease?
    Vaile JH; Dyke L; Kherani R; Johnston C; Higgins T; Russell AS
    Clin Exp Rheumatol; 2000; 18(4):433-8. PubMed ID: 10949716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases.
    Eissfeller P; Sticherling M; Scholz D; Hennig K; Lüttich T; Motz M; Kromminga A
    Ann N Y Acad Sci; 2005 Jun; 1050():327-39. PubMed ID: 16014549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of anti-nuclear antibodies from filter paper blood clots using indirect immunoenzyme technique: preliminary experience and results.
    Chopra A; Anuradha V; Edmonds J
    J Assoc Physicians India; 2000 May; 48(5):493-6. PubMed ID: 11273141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation.
    Moder KG; Wener MH; Weisman MH; Ishimori ML; Wallace DJ; Buckeridge DL; Homburger HA
    J Rheumatol; 2007 May; 34(5):978-86. PubMed ID: 17407218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arthralgias, myalgias, facial erythema, and a positive ANA: not necessarily SLE.
    Alarcón GS
    Cleve Clin J Med; 1997; 64(7):361-4. PubMed ID: 9223765
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of substrates for the detection of antinuclear antibodies in normals and in patients with connective tissue and other diseases.
    Lipscomb MF; Cope LD; Stephens GL; Deng JS; Gilliam JN
    Diagn Immunol; 1984; 2(3):181-7. PubMed ID: 6388982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of antinuclear antibody connective tissue disease screen.
    López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
    Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases.
    Shovman O; Gilburd B; Zandman-Goddard G; Yehiely A; Langevitz P; Shoenfeld Y
    Autoimmunity; 2005 Feb; 38(1):105-9. PubMed ID: 15804711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases?
    Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S
    Arch Immunol Ther Exp (Warsz); 2001; 49(6):423-30. PubMed ID: 11814236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the clinical immunology laboratory in the diagnosis and monitoring of connective tissue diseases.
    Aziz KA; Faizal AA
    Saudi Med J; 2004 Dec; 25(12):1796-807. PubMed ID: 15711644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clues for previously undiagnosed connective tissue disease in patients with trigeminal neuralgia.
    Nascimento IS; Bonfá E; de Carvalho JF; Saad CG; Vendramini MB; Teixeira MJ; Nóbrega JC; Viana VS
    J Clin Rheumatol; 2010 Aug; 16(5):205-8. PubMed ID: 20661065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ANA-negative SLE presenting with nephritis and oculomotor palsy--a case report.
    Sircar S; Taneja VA; Kansra U
    Indian J Pathol Microbiol; 1997 Oct; 40(4):539-42. PubMed ID: 9444868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus.
    Sjöwall C; Sturm M; Dahle C; Bengtsson AA; Jönsen A; Sturfelt G; Skogh T
    J Rheumatol; 2008 Oct; 35(10):1994-2000. PubMed ID: 18785312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevalence and diagnostic value of antinuclear antibodies without identified antigenic target: a retrospective study of 90 patients].
    Feki S; Frikha F; Ben Hadj Hmida Y; Abed S; Ben Ayed M; Turki H; Hachicha J; Baklouti S; Bahloul Z; Masmoudi H
    Rev Med Interne; 2012 Sep; 33(9):475-81. PubMed ID: 22658165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura.
    Altintas A; Ozel A; Okur N; Okur N; Cil T; Pasa S; Ayyildiz O
    J Thromb Thrombolysis; 2007 Oct; 24(2):163-8. PubMed ID: 17436144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical appraisal of the pattern of antinuclear antibodies (ANA) testing requested over a six month period at the "Escola Paulista de Medicina" (EPM), São Paulo.
    Quaresma MR; Krauthamer A; Ferraz MB; Leser PG; Atra E
    Rev Paul Med; 1993; 111(3):391-6. PubMed ID: 8108631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
    Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
    Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Undifferentiated connective tissue disease: clinical and serological profile of 578 patients followed for five years: disease course, prognosis and therapy].
    Bodolay E; Szegedi G
    Orv Hetil; 2002 Feb; 143(5):229-33. PubMed ID: 11875835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.